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Abstract (249 words) 
Background 
Foot drop in people with multiple sclerosis (pwMS) often managed with assistive technologies, 
such as functional electrical stimulation and ankle foot orthoses. No evidence synthesis exists for 
the psychometric properties of outcomes used to evaluate the efficacy of these interventions.  
Objective  
This systematic review aimed to identify the outcome measures reported to assess the benefits of 
assistive technology for pwMS and then synthesize the psychometric evidence in pwMS for a 
subset of these measures.  
Methods  
Two searches in eight databases were conducted up to May 2017. Methodological quality was 
rated using the COSMIN guidelines. Overall level of evidence was scored according to the 
Cochrane criteria.  
Results  
The first search identified 27 measures, with the 10m walk test, gait kinematics and Physiological 
Cost Index (PCI) most frequently used. The second search resulted in 41 studies evaluating 10 
measures related to walking performance. Strong levels of evidence were found for the internal 
consistency and test-retest reliability of the Multiple Sclerosis Walking Scale-12 and for the 
construct validity for Timed 25 Foot Walk. No psychometric studies were identified for gait 
kinematics and PCI in pwMS. There was a lack of evidence for measurement error and 
responsiveness. 
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Conclusion  
Although a strong level of evidence exists for some measures included in this review, there was 
an absence of psychometric studies on commonly used measures such as gait kinematics. Future 
psychometric studies should evaluate a wider range of walking related measures used to assess 
the efficacy of interventions to treat foot drop in pwMS.  
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Introduction  
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous 
system that typically strikes adults [1]. There is a wide variability among the symptoms, with gait 
impairments being one of the most common [2]. People with MS (pwMS) rate the impairment of 
their gait as being an inhibiting factor in their everyday life, sometimes even in relatively early 
stages of the disease [3,4]. 
One of the most common gait impairments is foot drop, which is the reduced dorsiflexion of the 
ankle during the swing phase of gait, potentially leading to trips or falls. Foot drop can be caused 
by weakness of the dorsiflexor muscles, impaired neural control causing co-contraction of agonist 
and antagonist muscles and increased tone in the plantarflexor muscles [5]. In pwMS foot drop 
can also be caused by increased motor fatigability, which is described as the exercise-induced 
reduction in the ability of the muscles to produce force or power [6]. Two common interventions 
to treat foot drop are functional electrical stimulation and ankle foot orthoses. The most 
commonly used ankle foot orthoses restrain the movement of the foot and thus reduce foot drop, 
but they do not allow active control of the ankle, which may result in an abnormal gait pattern 
[7]. On the contrary, functional electrical stimulation involves electrical stimulation that is 
applied to the common peroneal nerve, eliciting the desired contraction to produce ankle 
dorsiflexion during the swing phase of gait. The advantage of functional electrical stimulation is 
that it facilitates a more normal gait pattern, increases walking speed and decreases the 
physiological cost of gait [8,9].  
The effects of functional electrical stimulation and ankle foot orthoses on walking performance is 
currently evaluated via a wide variety of outcome measures including, for example, timed 
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walking tests [e.g. 6-Minute Walk test (6MWT), Timed 10-Meter Walk (10mWT), Timed 25 
Foot Walk (T25FW)] or patient or clinician reported instruments and rating scales [e.g. Multiple 
Sclerosis Walking Scale-12 (MSWS-12), Hauser Ambulation Index (HAI), Dynamic Gait Index 
(DGI)]. Instrumental motion analysis techniques are also used to objectively quantify the gait 
pattern. A comprehensive assessment of three-dimensional kinematics and kinetics can reveal 
minimal changes that cannot be observed visually [10]. For this reason, three-dimensional (3D) 
gait analysis is widely used to discriminate between normal and abnormal gait patterns and to 
evaluate responses to interventions in a variety of populations, such as stroke [11], cerebral palsy 
[12] and Parkinson’s disease [13,14].  
 The outcome measures used to assess the efficacy of interventions such as assistive technology 
to treat foot drop need to be valid, reliable and responsive to change. Several studies have 
evaluated the psychometric properties of outcome measures used to assess the effects of ankle 
foot orthoses and functional electrical stimulation to treat foot drop (e.g. Goldman et al [15], 
Stellman et al [16], Learmonth et al [17,18]). However, no systematic review exists that has 
evaluated both the evidence and the methodological quality of studies describing the 
psychometric properties of such outcome measures.  
We, therefore, aimed to (i) identify studies that evaluated the effects of ankle foot orthoses and 
functional electrical stimulation in pwMS and then (ii) synthesize the available psychometric 
evidence for the designated subset of, walking performance, effort of walking and lower limb 
function, outcome measures identified. In so doing, we hoped to augment the evidence-base 
available to optimize the appropriate selection of outcome measure(s) to evaluate the efficacy of 
assistive technology to treat foot drop in pwMS.  
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Methods 
First search: overview of outcome measures  
The purpose of the first search of the literature was to identify those studies that assessed the 
effects of either functional electrical stimulation or ankle foot orthoses used to treat foot drop in 
pwMS. From these studies we identified the outcome measures used and the frequency of their 
use. 
Search strategy and study selection 
A comprehensive search of eight databases, including MEDLINE (1963-5/2017), CINAHL 
(1969-5/2017), EMBASE (1974-5/2017), SCOPUS (1963-5/2017), PsycINFO (1963-5/2017), 
AMED (1967-5/2017), SPORTDiscus (1963-5/2017) and Web of Science (1967-5/2017) was 
conducted in order to identify the articles that met the inclusion criteria. The search strategy 
included synonyms and keywords for functional electrical stimulation (e.g. ‘Functional Electrical 
Stimulation’, ‘foot drop stimulation’ and ‘common peroneal stimulation’) and ankle foot orthoses 
(e.g. ‘Ankle Foot Orthoses’ and ‘splints’) and the population of interest (e.g. ‘multiple sclerosis’ 
and ‘demyelinating disease’). The full strategy has been included as supplementary material.  
The inclusion criteria for this search were: a) studies that have assessed the use of functional 
electrical stimulation or ankle foot orthoses to treat foot drop in pwMS and b) studies that 
included outcome measures that evaluate function, walking performance, fatigue and quality of 
life (QoL). The exclusion criteria were: a) studies that used other forms of electrical stimulation 
(i.e. not functional) and those that evaluated orthoses for other joints than the ankle, b) studies 
that were reviews (i.e. systematic, meta-analysis, etc.), conference abstracts and editorials and c) 
studies in languages other than English, Greek or Dutch.  
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Two independent researchers (GA, MvdL) were involved in the screening of the articles for 
inclusion. After exclusion of irrelevant articles based on the titles and abstracts, the full-text of 
the remaining articles was examined for their eligibility. Reference lists of articles included in the 
review were searched for potentially relevant articles that were not retrieved in the original 
search. If any differences in opinion existed, consensus was made through discussion and a third 
reviewer (TM) was available if consensus between the primary two reviewers was not reached. 
From the eligible articles, we extracted the outcome measures that were employed to assess the 
effects of functional electrical stimulation or ankle foot orthoses and recorded the frequency of 
these measures being used.  
Principal search: systematic review of the psychometric properties of outcome measures  
The second and principal search was conducted to identify studies that evaluated the 
psychometric properties of outcome measures that assess walking performance, effort of walking 
and lower limb function in pwMS.  
Search strategy and study selection 
A similar protocol for the second search was followed as the one described above. A 
comprehensive search of MEDLINE (1976-5/2017), CINAHL (1995-5/2017), SCOPUS (1999-
5/2017), EMBASE (1974-5/2017), PsycINFO (1963-5/2017), AMED (1967-5/2017), 
SPORTDiscus (1963-5/2017) and Web of Science (1967-5/2017) databases was conducted by 
combining the outcome measures of walking performance, effort of walking and lower limb 
function which were identified in the first search. The search strategy included keywords and 
synonyms of the population of interest (see first search), a subset of the identified outcome 
measures (e.g. ‘3D gait analysis’, ’10m walk test’, etc.) and a search filter for identifying studies 
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evaluating measurement properties, developed by Terwee et al [19]. The full search strategy is 
included as supplementary material.  
The inclusion criteria for our second search were: studies that assessed the psychometric 
properties of a subset of the outcomes identified in the first search, namely those assessing 
walking performance, lower limb function and effort of walking. Although we acknowledge the 
importance of outcome measures such as QoL and fatigue, we decided to restrict the outcome 
measures in this review to those measures that are potentially directly affected by the use of 
functional electrical stimulation and ankle foot orthoses. Further, the psychometric evidence for 
fatigue measures used in MS has been the subject of a previous review [20]. The exclusion 
criteria were: a) studies that were reviews (e.g. systematic and meta-analyses), abstracts from 
conferences or editorials, and b) full texts in peer reviewed journals published in languages other 
than English, Greek or Dutch. The procedures used to select the final set of papers were the same 
as those described for the first search.  
Methodological quality  
The methodological quality of the studies identified in the second search was assessed using the 
Consensus-based Standards for the selection of Health Measurement Instruments (COSMIN). We 
chose the COSMIN checklist since is used to obtain a score for the methodological quality of a 
study evaluating one or more measurement properties of a particular outcome measure [21,22]. 
The COSMIN checklist has been assessed for the inter-rater agreement and reliability of each 
item, with the percentage agreement being appropriate, but the kappa coefficients for each item 
being relatively low [23]. However, to overcome low inter-rater agreement in scoring items, we 
familiarized with the grading process and developed specific guidelines as recommended by the 
developers of COSMIN. The COSMIN-checklist consists of nine boxes (internal consistency, 
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reliability, measurement error, content validity, structural validity, construct validity, cross-
cultural validity and responsiveness) with each box including 5-18 items. The reviewer selects 
the measurement properties evaluated in the study and scores the specific item-lists with ‘poor’, 
‘fair’, ‘good’ or ‘excellent’ depending on the design and execution. The lowest score from the 
rated items determines the methodological quality of the measurement property [24]. Two 
reviewers (GA, MvdL) used the COSMIN checklist to rate the methodological quality of the 
measurement properties in all studies. Any disagreements in ratings were resolved through 
discussion.  
As previously mentioned, in order to be consistent in our ratings we developed guidelines for the 
rating of specific questions/items in each of the measurement properties in the COSMIN 
checklist. For example, all studies that used the EDSS as a comparator instrument were rated 
under the measurement property of construct validity, even if the authors stated that criterion 
validity was assessed. The questions for missing items and how they were handled was scored as 
‘not applicable’ for measures that were not self-reported scales. For studies assessing within-day 
test-retest reliability, the items for patients being stable and the time interval being appropriate 
were rated as excellent.  
The quality of the results of the psychometric properties of the outcome measures was assessed 
using the quality criteria by Terwee et al [25], which were recently revised by the authors [26]. 
The quality of the results of the psychometric properties was rated as ‘positive’ (+), 
‘indeterminate’ (?) or ‘negative’ (-) depending on the methods and results of the studies (Table 
1).  
Data synthesis 
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The overall level of evidence for each outcome measure was reported according to the 
recommendations of the Cochrane Back Review Group. This overall score was given in relation 
to the methodological quality of the study and the results of the measurement properties. The 
evidence was rated as ‘strong’ (consistent (positive) findings in multiple studies of good 
methodological quality or in one study of excellent methodological quality), ‘moderate’ 
(consistent (positive) findings in multiple studies of fair methodological quality or in one study of 
good methodological quality), ‘limited’ (one study of fair methodological quality), ‘conflicting’ 
(both positive and negative findings), ‘unknown’ (only studies of poor methodological quality) 
[27]. For instance, if the intra-rater reliability for a particular outcome measure had one study of 
poor quality and one of good quality showing positive results, the overall score was ‘moderate’. 
Likewise, if there were four studies of fair methodological quality but only one with having a 
positive score for the quality of the results, the overall score was ‘limited’.  
Results  
First search: overview of outcome measures  
After a systematic search of the eight databases, we retrieved 1393 titles for screening according 
to our inclusion criteria (Figure 1). We retained 34 articles and identified 27 outcome measures 
evaluating lower limb function, walking performance, effort of walking, fatigue and QoL. These 
outcomes measures were either self-reported measures [seven measures e.g. Fatigue Severity 
Scale (FSS), MSWS-12] or objective assessments [20 measures e.g. 6MWT, Multiple Sclerosis 
Functional Composite (MSFC), spatiotemporal gait parameters]. The most frequently used 
outcome measures were walking speed (mostly recorded over 10 meter distance), 3D gait 
kinematics and the Physiological Cost Index (PCI) (Figure 2).  
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Principal search: systematic review of the psychometric properties of outcome measures  
Description of included studies 
The systematic search of eight databases resulted in the identification of 2488 potentially relevant 
titles. After independent screening according to the inclusion and exclusion criteria, we retained 
36 articles with further reference citation tracking resulting in five additional articles (Figure 1). 
Four studies [28-31] were excluded at the full-text screening stage because they aimed at 
validating a previously reported minimal clinically important difference (MCID) or cut-off points 
for a certain outcome measure and did not validate the outcome measure itself. Although of 
interest, the methodology of these studies is different from those reporting the psychometric 
properties of the outcome measures themselves and are therefore not appropriate to be assessed 
using the COSMIN checklist and Terwee criteria. In total, we included 41 articles reporting the 
psychometric properties of 10 outcome measures [MSFC, MSWS-12, spatiotemporal parameters, 
10mWT, T25FW, 2 Minute Walk Test (2MWT), 6MWT, Rate of Perceived Exertion (RPE), 
peak oxygen uptake (VO2 peak) & reaction time/movement time (RT/MT)] which all have been 
used to assess the effects of assistive technology to treat foot drop. Using the COSMIN taxonomy 
the following measurement properties were evaluated: reliability was assessed in 18 studies 
[(intra-rater n=3; inter-rater n=3; test-retest n=14), 8 outcome measures], measurement error in 
four studies (six outcome measures) and internal consistency in six studies (one outcome 
measure). Hypothesis testing/construct validity was evaluated in 15 studies (nine outcome 
measures) and responsiveness was assessed in 15 studies (seven outcome measures). Most 
studies assessed the MSWS-12 (n=12), followed by the 6MWT (n=11) and the T25FW (n=11). 
The agreement between the two raters (GA & MvdL) in the items of all the measurement 
11 
 
properties was 94.8% and for the final scores of each property the agreement was 94.7%. Upon 
discussion any disagreement regarding the rating of the items or the total score of each property 
was resolved.  Studies included pwMS with relapsing remitting (RR), secondary progressive 
(SP), primary progressive (PP) and clinically isolated syndrome (CIS) with EDSS levels ranging 
from 0-8.5, with some studies not reporting this information [32-36]. The majority of the studies 
reported a mean of EDSS of four or more and five studies reported a mean EDSS of six [17,37-
40]. The sample size was 6796 in total for the 41 studies, with the number of females (n=2109) 
exceeding the number of males (n=972) and with some studies not reporting the gender of the 
participants [35-34,41-42]. Table 2 presents an overview of the results together with the 
COSMIN rating and the rating of the quality of the results according to the revised Terwee 
criteria [24-26]. 
Methodological quality and strength of evidence 
Reliability 
The methodological quality of the studies was rated according to the COSMIN checklist as 
‘good’ (n=3) [18,33,43], as ‘fair’ (n=3) [15,34,44] and ‘poor’ (n=12) [17,35-36,38,40,45-51]. The 
main reasons for a lower score included not reporting the intraclass correlation coefficient (ICC) 
or weighted Kappa, not describing the ICC model used, small sample size and the lack of an 
explicit statement that the repeated measurements were independent. Using the revised Terwee 
quality criteria [25-26], the evidence for reliability in 13 studies (seven outcome measures) 
[15,17-18,33-34,36,43-45,47-48,50-51] were rated as ‘positive’ and the remaining five (four 
outcome measures) [35,38,40,46,49] were rated as ‘indeterminate’ because neither ICC nor 
weighted Kappa were reported. From the eight outcome measures that were evaluated for 
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reliability (intra- & inter-rater, test-retest), seven of them demonstrated good and excellent values 
of ICC ranging from 0.86-0.96 and only for RPE the ICC values were moderate (0.706).  
Measurement error 
Of the four studies that evaluated measurement error (six outcome measures), the methodological 
quality of three [17,48,50] was rated as ‘poor’ due to a small sample size (n<30) and due to 
testing conditions not being similar. The methodology in one study [18] was rated as ‘fair’ 
because it was unclear whether the patients were stable in the interim period. The quality of the 
results for measurement error in all four studies was rated as indeterminate (‘?’) because in none 
of the studies the Minimal Important Change (MIC) values was reported, which is required to 
interpret whether the measurement error is acceptable [52].   
Internal consistency 
There were six studies that evaluated internal consistency. The methodological quality of four 
[33-34,53-54] was rated as ‘excellent’, for one [55] it was rated as ‘good’ and one [56] as ‘poor’ 
due to a small sample size. All six studies evaluated the MSWS-12 and were rated as positive 
(‘+’) for the quality of their results.   
Hypothesis testing/construct validity 
Fifteen studies assessed construct validity, with only one [40] with an ‘excellent’ methodological 
quality and one in which was rated as ‘good’ [57]. The methodological quality of seven 
[33,41,43,55,58-60] was rated as ‘fair’ either because the hypotheses were vague or due to 
limited information regarding the comparator instruments and its psychometric properties. The 
other studies [16,37,51,56,61-62] were rated as ‘poor’ due to a small sample size or the absence 
of information regarding the comparator instruments. Applying the Terwee quality criteria [25-
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26], the quality of the results reported in 10 studies [16,33,37,40,43,55-59] was rated as positive 
(‘+’) and in five studies [41,51,60-62] as indeterminate (‘?’) as the correlations presented were 
with unrelated constructs. The construct validity of seven of the studies reporting on six 
laboratory based measures and one self-perceived scale of walking performance used the EDSS 
as a comparator instrument. The comparator instrument in other studies were outcome measures 
such as the MSWS-12, Multiple Sclerosis Impact Scale-29 (MSIS-29), accelerometry and O2 cost 
of walking. Table 2 includes information regarding the comparator instruments and correlation 
coefficients presented in studies assessing construct validity. 
Responsiveness  
Responsiveness was evaluated in 15 studies, with the methodological quality of nine [32-
33,39,41,63-67] rated as ‘fair’ and the remainder classed as ‘poor’ [35,38,42,60,68-69]. Most of 
the studies had a vague hypothesis or did not use appropriate statistical methods and this lowered 
their rating. Only four studies [39,64-66] investigating the MSWS-12, 10mWT, T25FW, 2MWT 
and 6MWT received a ‘positive’ rating and the remaining 11 [32-33,35,38,41-42,60,63,67-69] 
were rated as ‘indeterminate’ due to correlations with unrelated constructs or the lack of 
differences between relevant groups. Of the 15 studies evaluating responsiveness, only two 
studies [39,65] reported on the MCID (MIC) for the 10mWT, T25FW and 6MWT. 
Level of evidence – data synthesis 
The overall levels of evidence for the psychometric properties of each outcome measure are 
summarized in Table 3. It was found that the MSWS-12 has strong positive evidence for its 
internal consistency and test-retest reliability, moderate positive evidence for its construct 
validity when compared to MSIS-29 and O2 cost of walking and limited positive evidence for its 
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responsiveness. The MSFC showed moderate positive evidence for its intra-rater reliability and 
construct validity, while for the remaining measurement properties, including responsiveness, the 
evidence was ‘unknown’. For lower limb reaction/movement time, there was limited positive 
evidence for construct validity, but for responsiveness the evidence was ‘unknown’. Strong 
evidence was found for the construct validity of the T25FW while for responsiveness and for 
test-retest reliability the evidence was moderately positive. Spatiotemporal parameters were 
classed as having a limited positive level of evidence for construct validity. For the 10mWT the 
level of evidence for its responsiveness was moderately positive, while for the other measurement 
properties this was ‘unknown’. Limited positive evidence was found for the responsiveness of the 
2MWT. For the 6MWT, the level of evidence for responsiveness and test-retest reliability was 
moderately positive, while the evidence for the inter-rater reliability was limited positive. The 
level of evidence for the measurement properties assessed for VO2 peak and RPE were all 
‘unknown’.  
Discussion  
The first search of the present systematic review identified 27 outcome measures, assessing self-
reported and objectively measured walking performance, self-perceived fatigue, effort of 
walking, QoL, balance, falls and lower limb function, that had been used in studies assessing the 
effects of assistive technology to treat foot drop in pwMS. The most frequently used measure was 
the 10mWT (n=19), followed by 3D gait kinematics (n=12) and PCI (n=10). Interestingly, 
although 3D gait kinematics was one of the most frequently used outcome measures to assess the 
effects of assistive technology to treat foot drop, its psychometric properties have not yet been 
reported for this specific population [10]. Similarly, there were no psychometric studies identified 
for PCI for the MS population. However, studies into the psychometric properties for 3D gait 
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kinematics have demonstrated that 3D gait analysis is a reliable, valid and responsive tool for 
characterizing gait in stroke sufferers [70], CP [71-73] and many musculoskeletal disorders [74-
75]. Similarly, the construct validity of the PCI has been assessed in the subacute stroke 
population and its reliability documented in children with cerebral palsy [76-77].  
The second, and main, search for studies assessing the psychometric properties of the 20 outcome 
measures related to walking performance, lower limb function and effort of walking identified in 
the first search, revealed 41 studies that evaluated only 10 of these twenty outcomes. Of those 10 
measures, the MSWS-12 was found to have a strong level of evidence for its internal consistency 
and test-retest reliability and the T25FW for construct validity. Moderate evidence was found for 
the test-retest reliability and responsiveness of the 6MWT and the responsiveness of the 10mWT.  
Short distance walking tests, such as the 10mWT and T25FW have been classified as reliable 
owing to ICC values of 0.7 and over. However, there are indications that walking speed, as 
measured over such short distances, may not be appropriate to assess the benefits of functional 
electrical stimulation for community walkers with relatively low levels of disability. For 
example, Miller et al [78] found that pwMS who walked faster than 0.8m/s did not increase their 
walking speed in the T25FW with the assistance of functional electrical stimulation, while those 
with a slower walking speed than 0.8m/s did.  
De Vet et al [79] distinguished two aspects of reliability, namely consistency (or relative 
reliability), which is assessed by the ICC and secondly measurement error (or absolute 
reliability), which is reported by measures like standard error of measurement (SEM), minimal 
detectable change (MDC) and the Limits of Agreement (LoA). Although ICC values are 
informative, these are greatly dependent on inter-subject variance in the outcome measure. The 
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knowledge of the measurement error of a particular measure is essential for both researchers and 
clinicians when selecting a reliable outcome as both need to establish whether an “improvement” 
in a patient’s walking performance, with the use of assistive technology, is due to measurement 
error or a ‘true’ change as a result of the intervention [80]. This is best achieved via the 
implementation of MDC data, the value beyond which, in this instance, a difference between 
performance with and without assistive technology can be considered a true change. In our 
review, of the 18 studies evaluating ‘relative’ reliability, only four also reported the measurement 
error of six outcomes (MSWS-12, 10mWT, T25FW, 6MWT, RPE and VO2peak). The MDC was 
reported to be 22 points, 2.7s and 88 meters for the MSWS-12, T25FW and 6MWT respectively 
[18]. Paltamaa et al [48] reported an SEM of 0.09 for the 10mWT that indicates an MDC (95%) 
of 2.4s. Heine et al [50] reported an SEM of 1.1 and 0.131 for RPE and VO2peak respectively, 
indicating an MDC (95%) of 3.04 for RPE and 0.36 Lmin-1 for VO2peak. However, the strength 
of the results in these studies rated as ‘indeterminate’ because the MIC values were not reported. 
According to Terwee et al [81], the value of the measurement error needs to be considered in 
relation to MIC (also referred to as the MCID) values in order to determine whether the 
measurement error of an outcome measure is acceptable for use in research or clinical practice. If 
the measurement error is exceeding MIC, it is difficult to interpret whether the observed changes 
are clinically relevant and are not just because of measurement error [52,81]. Another issue to 
consider is that patient-related factors, such as medications and comorbidities, can influence 
clinical outcome measurement findings by contributing to measurement error. Many people with 
MS using medications and have co-morbidities and symptoms such as fatigue, which may change 
over a period of several weeks or even days [82-83]. These factors are likely to affect outcome 
measures, both in test-retest reliability studies and clinical trials.  One of the items in COSMIN 
checklist for reliability and measurement error is: ‘Were patients stable in the interim period on 
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the construct to be measured?’ For an ‘excellent’ score for this item authors need to provide 
evidence that the patients were stable. However, none of the papers, including those with 
repeated assessment over more than two weeks [18,50] reported this evidence. 
The methodological quality of the 41 studies rated according to the COSMIN criteria revealed 
that both the analysis and reporting of the psychometric properties of outcome measures is often 
inappropriate. For example, the methodological quality of responsiveness studies was often only 
rated as ‘fair’ and ‘poor’ because the hypotheses were not reported or because there was a lack of 
information regarding the comparator instruments (often EDSS) and their psychometric 
properties. Another potential problematic issue with evaluating responsiveness was that in eight 
of the 14 studies there was no intervention and the (often assumed) hypothesis was that pwMS 
would deteriorate over the time frame of the study, which ranged from one to two years.  
The comparator instrument in seven out of the 15 studies that evaluated validity was the EDSS, 
which has been widely accepted as a gold standard to measure disability in pwMS. However, its 
use as a gold standard to validate outcomes of walking performance may be less appropriate. The 
EDSS [84] is a scale that was developed over 30 years ago and even though studies have reported 
high inter- and intra-rater reliability and high correlations for face validity [85-86], there are other 
studies raising issues regarding its reliability and objectivity and whether it  can be considered a 
‘gold standard’ [87-88]. 
It should be noted that the aforementioned methodological issues in the studies included in this 
review do not imply that the outcome measures are not appropriate but instead that more 
psychometric studies with higher methodological quality are needed. When planning studies to 
assess the psychometric properties of outcome measures, researchers should consult standard 
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guidelines such as COSMIN in relation to the selection of appropriate study design, statistical 
analysis and reporting of methods and results.  
To our knowledge, this is the first review that evaluated the evidence for the psychometric 
properties of walking performance related measures used to assess the effect of assistive 
technology in pwMS. We used standardized criteria to evaluate both the methodological quality 
(COSMIN) and quality of the results [22,25]. To date, only two reviews have tried to highlight 
which are the most useful tools for walking assessment in pwMS. However, one was a narrative 
review of available outcome measures and offered little detail about psychometric properties 
[10]. The other was a topical review including some details of the psychometric properties of 
measures to assess walking disability, but which did not employ specific criteria to evaluate the 
evidence for their use [89]. Work has been published on the stroke population that evaluated, also 
using COSMIN criteria, the psychometric properties of walking performance measures [90]. This 
review concluded that most of the outcome measures were reliable and valid for use in the stroke 
population, but it was observed, similar to our findings, that there was a lack of evidence for the 
minimally important change and responsiveness. Two COSMIN reviews into the functional 
outcomes in the cerebral palsy population came to similar conclusions [91-92]. 
This review has several limitations. Firstly, the COSMIN checklist was originally designed for 
patient-reported outcome measures and not for performance-based measures such as the majority 
of those included in our review. However, as there is no specific checklist for performance-based 
measures we opted to use the COSMIN checklist since most of the items scored are also highly 
relevant to performance-based measures. Additional rules were specified for the ratings of items 
that were only applicable to patient-reported outcome measures. Another limitation is that only 
studies published in English, Greek or Dutch were included, which means that eligible studies in 
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other languages will likely have been excluded. Finally, in the majority of the included studies, 
the mean EDSS was four or more and five studies involved participants with a mean EDSS of 
six. The responsiveness and reliability of walking performance measures in pwMS with EDSS > 
4 may be different from those who are less affected by MS.  
Conclusion  
The present systematic review reported on the psychometric properties of outcome measures used 
to assess the effects of assistive technology to treat foot drop.  Forty-one studies were identified 
which reported information on the psychometric properties of only 10 of the previously identified 
20 measures related to walking performance. Strong levels of evidence were found for internal 
consistency and test-retest reliability of the MSWS-12 and the construct validity of the T25FW.  
Moderate evidence was found for the test-retest reliability and responsiveness of the 6MWT and 
for the responsiveness of the 10mWT. None of the outcome measures that were evaluated for 
measurement error had an acceptable level of evidence for this measurement property. Our 
findings do not indicate that the existing outcome measures included in this review are poor, but 
that there is a need for more high quality studies evaluating the psychometric properties of these 
measures. Future research should (i) investigate the psychometric properties, and in particular 
measurement error and responsiveness, of a wider range of walking performance related 
measures and (ii) use standard guidelines such as the COSMIN to increase methodological 
quality enabling clinicians and researchers to select appropriate outcome measures to assess the 
effects of assistive technology to treat foot drop.  
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Table 1 Quality criteria for measurement properties [25-26]. 
Measurement property  Rating* Criteria  
Reliability  
Internal consistency  + At least limited evidence for unidimensionality or positive 
structural validity AND Cronbach’s alpha(s) ≥0.70 and ≤0.95  
? Not all information for ‘+’ reported OR conflicting evidence for 
unidimensionality or structural validity OR evidence for lack of 
unidimensionality or negative structural validity  
- Criteria for ‘+’ not met 
Reliability  + ICC or weighted Kappa ≥0.70 
? ICC or weighted Kappa not reported 
- Criteria for ‘+’ not met 
Measurement error + SDC or LoA < MIC 
? MIC not defined 
- Criteria for ‘+’ not met 
Validity  
Construct validity 
(Hypothesis testing) 
+ At least 75% of the results are in accordance with the hypotheses 
? No correlations with instrument(s) measuring related construct(s) 
AND no differences between relevant groups reported 
- Criteria for ‘+’ not met 
Criterion validity  + Convincing arguments that gold standard is “gold” AND 
correlation with gold standard ≥0.70 
? Not all information for ‘+’ reported 
- Criteria for ‘+’ not met 
Responsiveness  
Responsiveness  + At least 75% of the results are in accordance with the hypotheses 
? No correlations with changes in instrument(s) measuring related 
construct(s) AND no differences between changes in relevant 
groups reported 
- Criteria for ‘+’ not met 
* + = positive rating; ? = indeterminate rating; - = negative rating 
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Table 2 Summary of the study characteristics, rating of the methodological quality using the COSMIN guidelines and rating of the quality of the results using the 
Terwee criteria [24-26]. 
Author/Year Patient 
characteristics  
COSMIN 
Measurement 
Property 
Results  Rating 
Methodological 
quality 
Quality of the 
results 
Choice reaction time & movement time (RT/MT) 
Apache et al 
(2002)58 
n = 178 ,RR, SP,PP 
EDSS 0-6.5 
Hypothesis 
testing 
rs = 0.84 with EDSS Fair a + 
Apache et al 
(2005)68 
n = 40, RR, SP 
EDSS median 4.5 
3 sessions in 1-year 
Responsiveness 
(no intervention) 
RT/MT mean change =16.6% (.1) Poor b ? 
 
MSFC 
Cohen et al 
(2000)45 
n = 10, SP   
EDSS mean 5.2 
6 sessions (2 per day 
over 2 weeks) 
Reliability Intra-rater: ICC = 0.97 (session 4-5) 
Inter-rater: ICC = 0.96 (session 7-8) 
Poor c + 
Cohen et al 
(2001)43 
n = 436, SP  
EDSS mean 5.2 
3 pre-baseline 
sessions over 28 days 
Reliability Intra-rater: ICC (over 4 sessions) = 0.87 Good d, e  + 
Hypothesis 
testing   
rs = -0.56  with EDSS   Fair o, q + 
 
Cutter et al 
(1999)41 
n = 378, RR, SP 
EDSS 0-6.5  
3 annual sessions  
Hypothesis 
testing 
rs = -0.22 with EDSS Fair a, o ,q ? 
Responsiveness 
(no intervention) 
Average composite change Z-score:  
Baseline = -0.07 
1-year = -0.07 
2-year = -0.16 
Fair q ? 
 
Hobart et al 
(2004)57 
n = 133, RR, SP,PP 
EDSS mean 3.1 
Hypothesis 
testing 
r = -0.64 with EDSS Good f, w  + 
 
Kalkers et al 
(2001)62 
n = 131, RR, SP,PP 
EDSS mean 3.1 
Hypothesis 
testing  
rs = -0.25 with T2 lesion load 
rs = -0.24 with T1 lesion load 
Poor h ? 
 
Kragt et al 
(2008)42 
n = 161, PP  
EDSS mean 5.0 
Responsiveness 
(no intervention)  
ES:  
EDSS = 0.23 
MSFC = 0.16 
Poor b ? 
 
Miller et al 
(2000)61 
n = 300 
EDSS 0-8.5 
Hypothesis 
testing 
rs = -0.80 with HRQoL Poor h ? 
 
MSWS-12  
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Baert et al 
(2013)66 
n = 284, RR, SP,PP 
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness  
(physical 
rehabilitation) 
AUC with Global Rating Scale:  
Whole group = 0.73  
EDSS≤4 = 0.64  
EDSS 4.5-6.5 = 0.77  
Fair a + 
Filipovic et al 
(2011)63 
n = 49, RR  
EDSS mean 3.0 
2 sessions (pre & 
post) 
Responsiveness  
(IVMP for 
1month) 
SRM = 1.05 
ES = 1.02 
RE (%) = 82.4  
Fair a ? 
 
Freeman et al 
(2013)32 
n = 70, RR, SP, PP 
3 annual sessions 
Responsiveness  
(no intervention) 
ES = -0.07 
SEM = 5.66 
r <0.35 with walking speed & RMI 
Fair j ? 
 
Hobart et al 
(2003)33 
Community sample: 
n = 602 
2 sessions (10 days 
apart) 
Hospital-based 
sample:  
PP MS = 78 
Steroids = 54 
2 sessions (6 weeks 
apart) 
Internal 
consistency 
Community sample: Cronbach’s α = 0.97 
PPMS sample: Cronbach’s α = 0.97 
Steroids sample: Cronbach’s α = 0.94 
Excellent  + 
Reliability  Community sample: Test-retest ICC = 0.94 Good d, e, k + 
Hypothesis 
testing  
Steroids sample: rs = 0.65 with EDSS  Fair i, q + 
Responsiveness 
(steroid 
treatment) 
With EDSS:  
ES = 0.45 
SRM = 0.45 
RE = 0.31 
Fair m, q, t  ? 
 
Learmonth et 
al (2013)18 
n = 82, RR, SP, PP 
EDSS mean 3.5 
2 sessions (7 days 
apart) 
Reliability  Test-retest: ICC(2,1) = 0.93 
 
Good k, t + 
Measurement 
error 
SEM = 8; CV (5) = 27 
MDC95 = 22; %MDC95 = 53% 
Fair i, m, n ? 
 
McGuigan et 
al (2004)60 
Community sample = 
149 
Outpatient sample = 
53  
RR, SP, PP  
EDSS mean 4.0 
2 sessions 
Hypothesis 
testing 
rs = 0.84 with EDSS Fair a, o, q ? 
 
Responsiveness 
(no intervention)  
Z-score = -2.87 Poor b ? 
 
Motl et al 
(2008)55 
n = 133, RR, SP, PP  
EDSS mean 4.9 
1 session 
Internal 
consistency  
Cronbach’s α =.97 Good p, x + 
Hypothesis 
testing  
rs = .77 with MSIS-29 (physical) 
rs = .36 with MSIS-29 (psychological) 
rs = .80 with EDSS 
Fair q + 
34 
 
Motl et al 
(2010)56 
n = 24, RR  
PDDS median 1.0 
1 session 
Internal 
consistency 
Cronbach’s α = .95 Poor c + 
Hypothesis 
testing 
With O2 cost of walking at:  
CWS, r = 0.64 
FWS, r = 0.61 
SWS, r = 0.64 
With O2 consumption: 
CWS, r = 0.24 
FWS, r = 0.14 
SWS, r = 0.44 
Poor c + 
Motl et al 
(2011)34 
n = 269, RR  
3 sessions over a 
year 
Internal 
consistency 
Cronbach’s α:  
Baseline = .96 
6-month = .97 
12-month =  .97 
Excellent  + 
Reliability  Test-retest ICC(2):  
Across 6-months = .86 
Across 12-months = .87 
Fair i + 
Pilutti et al 
(2013)59 
n = 268, RR, SP,PP 
PDDS median 3.0 
1 session 
Hypothesis 
testing 
rs = .72 with T25FW 
rs = -.75 with 6MWT 
Fair q + 
Mokkink et al 
(2016)53 
n = 625, RR, SP, 
PP,PR, CIS 
EDSS median 3.5 
Internal 
consistency 
RMSEA = 0.078 
CFI = 1.000 
TLI = 0.999 
SRMR = 0.019 
Guttman’s lambda2 = 0.98 
Excellent + 
Engelhard et 
al (2016)54 
n = 293, RR, SP, 
PP,PR 
 
Internal 
consistency  
1D Rasch:  
BIC = 6112.5; AIC = 5933.7 
3D GRM: 
BIC = 5972.7; AIC = 5677.3 
Excellent  + 
      
FAP/ Spatiotemporal parameters 
Sosnoff et al 
(2011)37 
n = 13, RR, SP  
EDSS median 6.0 
1 session 
Hypothesis 
testing  
FAP: 
rs = -0.82 with T25FW 
rs = -0.49 with MSWS-12 
rs = -0.81 with EDSS 
Poor c + 
Pilutti et al 
(2013)59 
n = 268, RR, SP,PP  
PDDS median 3.0 
Hypothesis 
testing 
Speed with T25FW: r = -.68 
Cadence with T25FW: r = -.50 
Fair q + 
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1 session Speed with 6MWT: r = .67 
Cadence with 6MWT: r = .52 
10mWT 
Feys et al 
(2014)46 
n = 102, RR, SP,PP  
EDSS mean 4.6 
3 sessions within a 
day 
Reliability  Test-retest: 
Within-day variability (%) at usual speed: 
 -Community walkers (CW) = 22.6 
 -Limited CW = 26.6 
 -Most limited CW = 43.3 
 Within-day variability (%) at fastest speed: 
-CW = 12.1 
-Limited CW = 23.4 
-Most limited CW = 38.4 
Poor b ? 
 
Freeman et al 
(2013)32 
n = 70, RR, SP, PP  
3 annual sessions 
Responsiveness  
(no intervention) 
ES = 0.001 
r <0.35 with MSWS-12 & RMI 
Fair j ? 
 
Kempen et al 
(2011)64 
n = 156 , RR  
EDSS mean 2.5 
6 sessions in 6 years 
Responsiveness 
(no intervention)  
AUC = 0.79 with MFWC6 
AUC = 0.86 with MFWC5 
AUC = 0.74 with MFWC4 
AUC = 0.82 with MFWC3 
Fair j + 
Paltamaa et al 
(2005)48 
Test-retest n = 19 
Inter-rater n = 9 
RR, SP, PP  
EDSS 0-6.5 
2 sessions (1 week 
apart) 
Reliability  Test-retest: ICC = 0.91 
Inter-rater: ICC = 0.93 
Poor c + 
Measurement 
error  
Test-retest: SEM = 0.09m/s 
Inter-rater: SEM = 0.10m/s 
Poor c ? 
 
Paltamaa et al 
(2008)65 
Baseline n = 120 
Follow-up n = 109 
RR, PP  
EDSS median 2.0  
3 sessions in 2years 
Responsiveness 
(no intervention)  
AUC = 0.76 with EDSS 
MICdeterioration = -0.19 
 
 
Fair a + 
Stellman et al 
(2015)16 
n = 28, RR, SP, PP  
EDSS mean 3.2 
1 session 
Hypothesis 
testing 
r = 0.61 with accelerometry Poor c + 
Vaney et al 
(1996)38 
Reliability n = 25 
Responsiveness n = 
115 
EDSS mean 6.6 
5 sessions within-day 
Reliability  Test-retest: rs = -0.8 with RMI Poor c, u ? 
Responsiveness  
(physical & 
occupational 
therapy) 
Not adequate statistical information for 
responsiveness  
Poor y ? 
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Timed 25-Foot Walk 
Baert et al 
(2013)66 
n = 284, RR, SP,PP  
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness 
(physical 
rehabilitation)  
AUC with Global Rating Scale: 
Whole group = 0.50  
EDSS≤4 = 0.64  
EDSS 4.5-6.5 = 0.45  
Fair a + 
Coleman et al 
(2012)39 
n = 296, RR, RP, SP, 
PP   
EDSS mean 5.8 
4 sessions 
Responsiveness 
(dalfampridine 
treatment)  
rs = -0.39 with CGI 
MICD = 0.35 m/s 
Relative improvement = 17.2% 
Fair a + 
Filipovic et al 
(2011)63 
n = 49, RR  
EDSS mean 3.0 
2 sessions (pre & 
post) 
Responsiveness 
(IVMP for 1 
month)  
SRM = 0.55 
ES = 0.27 
RE (%) = 68.3 
Fair a, t ? 
 
Hobart et al 
(2013)40 
n = 533, RR, SP,PP  
EDSS mean 6.0 
9 sessions 
Reliability  Variability ranged from 10.03 – 11.44 Poor b ? 
Hypothesis 
testing  
r = -0.20 to -0.43 with MSWS-12 Excellent  + 
Kaufman et al 
(2000)35 
n = 133, SP  
3 sessions (6 month 
period) 
Reliability Not adequate statistical information for 
reliability 
Poor b ? 
 
Responsiveness  
(no intervention) 
Not adequate statistical information for 
responsiveness 
Poor b, h ? 
 
Larson et al 
(2013)44 
n = 36, RR  
EDSS mean 3.5 
2 sessions 1 week 
apart 
Reliability Test-retest ICC = 0.92 Fair c + 
Learmonth et 
al (2012)17 
n = 24 
EDSS mean 6.02 
2 sessions 1 week 
apart 
Reliability  Test-retest ICC(2,3) = 0.94 
 
Poor c + 
Measurement 
error 
SEM = 4.56s 
MDC95 = 12.6s 
Poor c ? 
 
Learmonth et 
al (2013)18 
n = 82, RR, SP, PP  
EDSS mean 3.5 
2 sessions (7 days 
apart) 
Reliability  Test-retest ICC(2,1) = 0.991 Good t + 
Measurement 
error 
SEM = 1s 
MDC95 = 2.7s 
% MDC95 = 36 
Fair i, m, n ? 
 
Schwid et al 
(2002)49 
n = 63 
EDSS 0-6.5 
5 sessions 
Reliability  Test-retest reliability: 
95% CI: ± 16% of patients baseline score 
Poor b ? 
 
van Winsen et 
al (2010)67 
n = 112, CIS, RR, 
SP, PP  
Responsiveness Sensitivity (%) = 25 
Specificity (%) = 90 
Fair a ? 
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EDSS mean 4.5 
2 sessions (pre & 
post) 
(IVMP for 6 
weeks)  
LR+ = 2.50 
LR- = 0.83 
Jensen et al 
(2016)69 
n = 105 
EDSS mean 5.6 
2 sessions 
Responsiveness 
(SR-Fampridine 
treatment)  
MCID = 1.3s 
%MCID = 14.2  
Poor h, y ? 
2-Minute Walk Test 
Baert et al 
(2013)66 
n = 284, RR, SP, PP  
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness 
(physical 
rehabilitation)  
AUC with Global Rating Scale:  
Whole group = 0.64  
EDSS≤4 = 0.74  
EDSS 4.5-6.5 = 0.60  
Fair a + 
Feys et al 
(2014)46 
n = 102, RR, SP,PP  
EDSS mean 4.6 
3 sessions within a 
day 
Reliability  Within-day variability (%):  
CW = 12.0 
Limited CW = 13.8 
Most limited CW = 26.3 
Poor b ? 
 
Filipovic et al 
(2011)63 
n = 49, RR  
EDSS mean 3.0 
2 sessions (pre & 
post) 
Responsiveness 
(IVMP for 1 
month)  
SRM = 0.89 
ES = 0.54 
RE (%) = 95.1 
Fair a ? 
 
Stellman et al 
(2015)16 
n = 28, RR, SP, PP  
EDSS mean 3.2 
1 session 
Hypothesis 
testing 
r = 0.79 with accelerometry 
 
Poor c + 
6-Minute Walk Test 
Baert et al 
(2013)66 
n = 284, RR, SP,PP  
EDDS mean 4.8 
2 sessions (pre & 
post) 
Responsiveness 
(physical 
rehabilitation)  
AUC with Global Rating Scale:  
Whole group = 0.68  
EDSS≤4 = 0.77  
EDSS 4.5-6.5 = 0.65 
Fair a + 
Feys et al 
(2014)46 
n = 102, RR, SP,PP  
EDSS mean 4.6 
3 sessions within a 
day 
Reliability  Within-day variability (%):  
CW = 10.1 
Limited CW = 15.7 
Most limited CW = 28.7 
Poor b ? 
 
Freeman et al 
(2013)32 
n = 70, RR, SP, PP  
3 annual sessions 
Responsiveness  
(no intervention) 
ES = 0.03 
 ‘general mobility’: r = 0.499 
Fair j ? 
 
Fry et al 
(2006)47 
n = 12, RR, SP, PP  
EDSS mean 3.6 
2 sessions (1 week 
apart) 
Reliability  Test-retest ICC = 0.96 
 
Poor c + 
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Goldman et al 
(2008)15 
n = 40, RR, SP, PP  
EDSS 0-6.5 
3 sessions (in 4 
hours) 
Reliability  Test-retest: ICC = 0.94 
Inter-rater: ICC = 0.91 
Fair t + 
Learmonth et 
al (2012)17 
n = 24 
EDSS mean 6.02 
2 sessions 1 week 
apart 
Reliability  Test-retest: ICC (2,1) = 0.96 Poor c + 
Measurement 
error 
SEM = 27.48m 
MDC95 = 76.2m 
Poor c ? 
 
Learmonth et 
al (2013)18 
n = 82, RR, SP, PP  
EDSS mean 3.5 
2 sessions (7 days 
apart) 
Reliability  Test-retest: ICC(2,1) = 0.96 Good t + 
Measurement 
error 
SEM = 32m 
MDC95 = 88m 
% MDC95 = 20 
Fair i, m, n ? 
 
Paltamaa et al 
(2005)48 
Test-retest n = 19 
Inter-rater n = 9 
RR, SP, PP   
EDSS 0-6.5 
2 sessions (1 week 
apart) 
Reliability  Test-retest: ICC = 0.96 
Inter-rater: ICC = 0.93 
Poor c + 
Measurement 
error 
Test-retest: SEM = 30.65 m 
Inter-rater: SEM = 35.85 m 
Poor c ? 
 
Paltamaa et al 
(2008)65 
Baseline n = 120 
Follow-up n = 109 
RR, PP  
EDSS median 2.0  
3 sessions in 2 years 
Responsiveness 
(no intervention)  
AUC = 0.76 with EDSS 
MICdeterioration = -55.06 
 
 
Fair a + 
Stellman et al 
(2015)16 
n = 28, RR, SP, PP  
EDSS mean 3.2 
1 session 
Hypothesis 
testing 
r = 0.68 with accelerometry 
 
Poor c + 
Toomey et al 
(2013)36 
n = 8 
1 session(4assessors) 
Reliability  Inter-rater: ICC = 0.984  
 
Poor c + 
RPE 
Heine et al 
(2015)50 
n = 31 RR, SP, PP 
EDSS mean 2.5 
2 sessions (1-3 
weeks apart) 
Reliability  Test-retest: ICC = 0.706 Poor z  + 
Measurement 
error 
SEM = 1.1 
SDCindividual  = 2.9 
SDCgroup = 0.52 
LoA = -2.9-2.9 
Poor z ? 
Cleland et al 
(2016)51 
n = 16 RR, SP, PP 
EDSS median 1.75 
Reliability  Test-retest: ICC = 0.870 Poor c + 
Hypothesis 
testing 
r = .691 with VO2 (L/min) 
r = .507 with VO2 (mL/kg/min) 
Poor c, h ? 
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2 sessions (6-10 days 
apart) 
VO2 peak      
Heine et al 
(2015)50 
n = 31 RR, SP, PP 
EDSS mean 2.5 
2 sessions (1-3 
weeks apart) 
Reliability  Test-retest: ICC = 0.933 for VO2 peak 
(mLkg-1min-1) 
Poor z + 
Measurement 
error 
VO2 peak (mLkg-1min-1):  
SEM = 1.7 
SDCindividual  = 4.6 
SDCgroup = 0.82 
LoA = -5.0-4.3 
Poor z ? 
      
 
COSMIN item rating: a: hypothesis vague or not formulated, possible to deduce; b: not appropriate statistical methods; c: small sample size; d: no description of 
ICC model used; e: assume that patients were stable in the interim period; f: expected magnitude of the correlations not stated; g: assumable that statistical 
methods were appropriate; h: no information about the psychometric properties of the comparator instruments; i: not clear how missing items were handled; j: 
unclear or not described what occurred in the interim period; k: assumable that measurements were independent; l: AUC or correlations not calculated; m: unclear 
if patients were stable; n: doubtful whether time interval was appropriate; o: poor description of the comparator instrument; p: no description of the % of missing 
data; q: some information on measurement properties or a reference; r: internal consistency not calculated for each subscale separately; s: no ICC, Spearman or 
Pearson’s correlations calculated; t: due to sample size; u: only correlations, not ICC calculated; v: minimal number of hypothesis formulated a priori; w: 
expected direction of the correlations or differences not stated; x: not described but can be deduced how missing items were handled; y: unclear what was 
expected; z: test conditions were not similar 
Abbreviations: AIC: Akaike information criterion; AUC: Area under the curve; BIC: Bayesian information criterion; CFI: comparative fit index; CGI: Clinician 
Global Impression; CIS: Clinically Isolated Syndrome; CWS: comfortable walking speed; ES: effect size; FWS: faster walking speed; GPCM: generalized partial 
credit model; GRM: graded response model; HRQoL: Health-related Quality of Life; ICC: Intraclass Correlation Coefficient; IVMP: intravenous 
methylprednisolone therapy; LoA: limits of agreement; LR: Likelihood ratio; MDC: minimum detectable change; MIC: minimal important change; MICD: 
Minimally important clinical difference; MFWC: Modified Functional Walking Categories; PDDS: Patient Determined Disease Steps; PP: Primary Progressive; r: 
Pearson’s correlations; rs: Spearman coefficient; RE: relative efficiency; RMI: Rivermead Mobility Index; RMSEA: root mean square error of approximation; 
RR: Relapsing Remitting; SDC: smallest detectable change; SEM: standard error of mean; SP: Secondary Progressive; SRM: standardized response mean; 
SRMR: root mean square residual; SWS: slower walking speed; TLI: Tucker-Lewis index. 
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Table 3 Level of evidence for each outcome measure identified in the principal search. 
Outcome 
measure 
Internal 
consistency 
Reliability Measurement 
error 
Hypothesis 
testing 
Responsiveness 
Intra-rater Inter-
rater 
Test-
retest 
        
RT/MT n/a n/a n/a n/a n/a + 
Limited 
? 
 Unknown 
        
MSWS-12 +++  
Strong 
n/a n/a +++ 
Strong 
?  
Unknown 
++ 
Moderate 
+ 
 Limited 
        
MSFC n/a ++ 
Moderate 
? 
Unknown 
n/a n/a ++ 
Moderate 
?  
Unknown 
        
Spatiotemporal 
parameters 
n/a n/a n/a n/a n/a + 
 Limited 
n/a 
        
10mWT n/a n/a ? 
Unknown 
? 
Unknown 
?  
Unknown 
?  
Unknown 
++  
Moderate 
        
T25FW n/a n/a n/a ++ 
Moderate 
?  
Unknown 
+++  
Strong 
++  
Moderate 
        
2MWT n/a n/a n/a ? 
Unknown 
n/a ?  
Unknown 
+ 
 Limited 
        
6MWT n/a n/a +  
Limited 
++ 
Moderate 
?  
Unknown 
? 
 Unknown 
++ 
 Moderate 
VO2 peak n/a n/a n/a ? 
Unknown 
?  
Unknown 
n/a n/a 
RPE n/a n/a n/a ? 
Unknown 
?  
Unknown  
?  
Unknown  
n/a 
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Figure 1 1. Preliminary search: identification of the outcomes measures that have been used to assess the effect of 
assistive technology for foot drop; 2. Principal search: studies evaluating the psychometric properties of outcome 
measures of walking performance, effort of walking and lower limb function. 
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Figure 2 Outcome measures identified in the preliminary search and the reported frequency of use.  
Abbreviations: MWP: measured walking performance; SRWP: self-reported walking performance; LLF: lower limb 
function; EoW: effort of walking; PF: perceived fatigue; spatiotemp. par.: spatiotemporal parameters; ROGA: 
Rivermead Observational Gait Analysis; EMG gait record: electromyography gait recording; mEFAP: modified 
Emory Functional Ambulation Profile; 10mWT: 10 meter Walk Test; T25FW: Timed 25 Foot Walk; 2MWT: 2 Minute 
Walk Test; 3MWT: 3 Minute Walk Test; 4MWT: 4 Minute Walk Test; 6MWT: 6 Minute Walk Test; MSFC: Multiple 
Sclerosis Functional Composite; MSWS-12: Multiple Sclerosis Walking Scale-12; HAI: Hauser Ambulation Index; 
CSRT: choice stepping reaction time; PCI: Physiological Cost Index; RPE: Rate of Perceived Exertion; ECW: energy 
cost of walking; FSS: Fatigue Severity Scale; SF-36: 36-Item Short Form Health Survey; COPM: Canadian 
Occupational Performance Measure; PIADS: Psychosocial Impact of Assistive Devices Scale; 9HPT: 9-Hole Peg 
Test; PASAT: Paced Serial Addition Test; MSIS-29: Multiple Sclerosis Impact Scale.  
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